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Genes important for mitochondrial function have been implicated in Parkinson’s disease (PD). Mitochondrial translation
initiation factor 3 (MTIF3) is a nuclear encoded protein required for the initiation of complex formation on mitochondrial
ribosomes.DysfunctionofMTIF3mayimpairmitochondrialfunctionanddopamineneuronsappeartobeparticularlyvulnerable
to oxidative stress, which may relate to their degeneration in PD. An association was recently reported between the synonymous
rs7669(C>T) in MTIF3 and PD in a German case-control material. We investigated rs7669 in a Swedish Parkinson case-control
material. The study revealed no signiﬁcant association of the individual genotypes or alleles with PD. When comparing the
combined TT/CT-genotypes versus the CC-genotype, we observed a signiﬁcant association (P = .0473) with PD. We also
demonstrated that the TT-genotype causes a signiﬁcant decrease in MTIF3 mRNA expression compared to the CC-genotype
(P = .0163). Our ﬁndings support the hypothesis that MTIF3 may be involved in the etiology of PD.
1.Introduction
Parkinson’s disease (PD) is the second most common neu-
rodegenerative disorder and aﬀects 1-2% of the population
over the age of 50 worldwide [1–4]. Several ﬁndings support
mitochondrial involvement in PD.
For example, the metabolite of the neurotoxin 1-methyl-
4-phenyl-1,2,3,6-tetrehydropyridine (MPTP); 1-methyl-4-
phenylpyridinium (MPP+) is a mitochondrial respiratory
chain complex I inhibitor and causes degeneration of
dopamine (DA) neurons in substantia nigra (SN) [5].
Another example is the pesticide rotenone, which also is
a complex I inhibitor, causing nigrostriatal degeneration
in rodents resembling the pathology of PD [6]. Mito-
chondrial DNA (mtDNA) encodes two ribosomal RNAs
(rRNAs), 22 transfer RNAs (tRNAs) and 13 proteins. The
mtDNA encoded proteins are all part of the oxidative
phosphorylation system responsible for generating energy
by aerobic metabolism, whereas the rRNAs and tRNAs
are needed for intramitochondrial protein synthesis [7].
Activity of complex I in the electron transport chain has
been reported to be reduced in SN and in platelets from
patients with PD [8]. Certain mtDNA polymorphisms have
been reported to be associated with PD, others to reduce
the risk [9]. Further evidence to support mitochondrial
dysfunction in PD comes from reports associating PD
with genetic variants in DNA polymerase gamma protein
(POLG), which is important for mtDNA replication and
repair [10]. The N-terminal of the human POLG protein
contains a short polyglutamine domain encoded by a CAG-
repeat. It has been reported that rare length variants of the
CAG-repeat in the POLG gene are associated with idiopathic2 Parkinson’s Disease
PD[10].Conditional knockout mice witha disruption ofthe
mitochondrial transcription factor A (Tfam) in DA neurons
(“MitoPark” mice) lend additional support to the hypothesis
of mitochondrial involvement in PD [11] .T h e s em i c eh a v e
respiratory chain deﬁciency in midbrain DA neurons and
show Parkinson-like motor disabilities, which are relieved by
L-dopa [11].
MTIF3 is required for the initiation complex forma-
tion on 55S mitochondrial ribosomes [12]. Dysfunction
of MTIF3 may aﬀect the expression of mtDNA-encoded
proteins,whichinturnmaycauseoxidativestress.Dopamine
neurons appear particularly vulnerable to oxidative stress,
which may be the cause of their degeneration in PD. To
date, ﬁve nuclear genes identiﬁed at PARK loci have been
suggested to directly or indirectly inﬂuence mitochondrial
function:α-synuclein,Parkin,DJ-1,PINK1,andLRRK2[13–
15]. Mutations in the serine-threonine kinase PINK1 gene
have been reported to be responsible for PARK6-associated
autosomalrecessivePD.ThePINK1proteinislocalizedtothe
mitochondriainmammaliancells[16].Theserine-threonine
kinase domain of PINK1 and the ortholog protein in
drosophilamelanogaster CG4523 havea300amino acidslong
homology region. This PINK1 homologue interacts with
CG11656-PA, whose closest mammalian ortholog protein
is MTIF3, supporting the hypothesis that MTIF3 is an
interactor protein for PINK1 and important in the etiology
of PD [17]. The aim of the present study was to analyze
the MTIF3 synonymous polymorphism rs7669 (Asp266Asp,
C > T) in a Swedish PD case-control material based on
the reported association with sporadic and familial PD in
a German case-control material [17]. In addition, we also
investigated possible diﬀerences in mRNA expression levels
betweenthethreegenotypesusingcelllinesfromPDpatients
and controls.
2.MaterialandMethods
2.1. DNA Material. The polymorphism rs7669 (C > T)
in MTIF3 was investigated in a Swedish PD case-control
material.Theethicalcommitteesofeachinstitution,Karolin-
ska Institutet Forskningsetikkommitt´ e Nord and Forskn-
ingsetikkommitt´ en, University of Gothenburg, approved the
study and each subject signed an informed consent. All
subjects were unrelated and of Swedish origin. A total of
381 PD patients were recruited: 211 at Karolinska Univer-
sity Hospital, Stockholm and 170 at Sahlgrenska Hospital,
Gothenburg(meanageatsamplecollection,67.7years;mean
ageofonset59.3years;59.3%men).AllsporadicPDpatients
fulﬁlled the “Brain Bank Clinical Diagnostic Criteria” for
idiopathic PD [18]. Control subjects were blood donors,
spouses to PD patients or individuals visiting hospitals or
care centers for non-neurological symptoms in Stockholm
(n = 135) and Gothenburg (n = 187) (n = 322; mean
age at sample collection, 58.7 years; 43.8% men). 52 of
the Stockholm PD patients and 38 of the Gothenburg PD
patientshadaself-reportedfamilialhistoryofPDwithoneor
more ﬁrst-, second- or third-degree relatives with PD. DNA
was extracted from blood samples according to standard
protocol.
2.2. Pyrosequencing. To genotype the genetic variant rs7669
in MTIF3 we used pyrosequencing, a method that analyzes
genetic variants by detecting the energy released when a
nucleotide is incorporated into a predeﬁned DNA strand
[19]. To test for genotyping errors we used water as
negative controls and resequenced some of the samples
chosen at random to conﬁrm the results. The following
primer sequences have been used; forward primer 5 -
CGTGCTTTCAGCAAAAATG-3 , biotinylated at the 5 -
end; reverse primer 5 -AAAGGACTGCAGACCAAGGA-
3 , and sequencing primer 5 -TCCTTATCATTTCCA-3 .
Polymerase chain reaction (PCR) was carried out with Taq
polymerase after which the biotinylated PCR product was
immobilizedonstreptavidin-coatedbeadsaccordingtoman-
ufacturer’sinstructions.TheimmobilizedDNAtemplatewas
captured onto ﬁlter probes (PyroMark Vacuum Prep Tool,
Biotage AB, Uppsala, Sweden). The ﬁlter probes were ﬂushed
with 70% ethanol, denaturation solution, washing buﬀer,
and the single-stranded template was annealed to a reverse
sequencing primer. All solutions were prepared according to
manufacturer’s instructions (Biotage AB, Uppsala, Sweden).
Samples were analyzed on an automated pyrosequencer
using a PSQ 96 System together with SNP Software and
SNP Reagent Kits (Biotage AB, Uppsala, Sweden). Genotype
distribution and allele frequencies were compared between
the diﬀerent groups using the Chi-square (χ2)t e s t[ 20].
Distribution of genotypes in controls was tested for con-
sistency with the Hardy-Weinberg equilibrium. Statistical
signiﬁcance levels were set at P<. 05.
2.3. Prediction of mRNA Secondary Structure. To evaluate
the eﬀect of rs7669 on the mRNA structure, the secondary
structureofMTIF3waspredictedusingthepubliclyavailable
online mfold program (version 3.2) [21, 22]. Partial MTIF3
mRNA sequences of 141 nucleotides including ﬂanking
sequences (70 nucleotides) on either side of the polymor-
phism were analyzed and compared to wild-type sequence.
2.4. Epstein-Barr Virus Transfection and Culture of Human B-
lymphocytes. B-lymphocytes were separated from peripheral
blood by standard protocols using Ficoll-Paque (GE Health-
careBio-SciencesCorp., Piscataway,NJ,USA).Thecellswere
cultivated in RPMI 1640 medium (SIGMA, St. Louis, MO,
USA) with 20% fetal calf serum and L-glutamine (200mM;
Invitrogen, Carlsbad, CA, USA), penicillin—streptomycin
(5000μg/ml; Invitrogen, Carlsbad, CA, USA), cyclosporine
(1μl/ml; Apoteket, Stockholm, Sweden), and ﬁltered super-
natant of Epstein-Barr virus (EBV) infected B95-8 cells. The
medium was changed twice a week until cell lines were
established at which time the cells were gradually frozen and
kept at −140
◦C until use. For mRNA quantiﬁcation, the
cellswerethawed,culturedforapproximatelytwoweeks,and
harvested when cell number reached 4-5 million cells.
2.5. Quantitative Real-Time PCR. Quantitative real-time
PCR (qRT-PCR) was performed on RNA from EBV
transfected B-lymphocytes from individuals representing
the three diﬀerent rs7669 genotypes (CC, CT, and TT).Parkinson’s Disease 3
Quantiﬁcation of MTIF3 mRNA expression levels for the
three diﬀerent genotypes was performed in samples from
six diﬀerent individuals per genotype. Individuals were
chosen only based on their rs7669 genotype regardless their
neurological status (CC genotype: 2 PD patients and 4
controls, CT genotype: 4 PD patients and 2 controls, and
TT genotype: 5 PD patients and 1 control). Total RNA
was isolated from the EBV-transfected B-lymphocytes using
RNeasy Mini Kit (Qiagen, Hilden, Germany) and quantiﬁed
by spectrophotometry at 260nm. cDNA was generated
from 1μg RNA by a modiﬁcation of the manufacturer’s
protocol using Deoxyribonuclease I, Ampliﬁcation Grade
(Invitrogen, Carlsbad, CA, USA), and SuperScript III Plat-
inum Two-Step qRT-PCR kit with SYBR Green (Invitrogen,
Carlsbad, CA, USA). qRT-PCR was performed on an ABI
Prism 7000 (Applied Biosystems, Foster City, CA, USA)
using SYBR Green I dye (Invitrogen, Carlsbad, CA, USA).
The samples were run in triplicates for the target gene
MTIF3 (forward primer 5 -ATCGCTTGCCCCAGCAC-3 ;
reverse primer 5 -TCATCCCCAGTTGATGAGG-3 )a n d
two housekeeping genes; beta-actin (forward primer 5 -
AACCGCGAGAAATCATGTTTG-3 ; reverse primer 5 -
CAGAGGCGTACAGGGATAGCA-3 ) and cyclophilin (for-
ward primer 5 -GACCCAACACAAATGGTTCC-3 ;r e v e r s e
primer 5 -GGCCTCCACAATATTCATGC-3 ). Ampliﬁca-
tion of a single gene product was conﬁrmed by monitoring
the dissociation curve as well as agarose gel electrophoresis.
Threshold cycle (Ct) values from the exponential phase of
the PCR ampliﬁcation plot were analyzed with ABI Prism
7000 SDS v1.2.3. Each Ct value for the target transcripts was
normalized to beta-actin and cyclophilin, using qBase v1.3.5
[23], based on the 2−ΔΔCt method [24]. The 2−ΔΔCt method
has been extended in the qBase software to include multiple
stable expressed reference genes to improve normalization
[23]. The quantiﬁcation of the expression was compared
between the three diﬀerent genotypes using Student’s t-test.
Signiﬁcance level was set at P<. 05.
3. Results
3.1.GenotypingandSecondaryStructureofmRNA. We found
all three genotypes of rs7669 (CC, CT and TT) in both PD
cases and controls. The observed frequencies of the controls
were in agreement with the Hardy-Weinberg equilibrium
(data not shown). Our analysis showed no signiﬁcant
association of any of the three individual genotypes or alleles
with PD (Table 1). When comparing the TT/CT genotypes
versustheCCgenotype,weobservedasigniﬁcantassociation
withsporadicPD(P = .0473).StratiﬁcationbyPDonsetinto
50 years or younger versus older than 50 years of age at onset
compared to age-matched controls revealed no associations
of genotype or allele distribution with disease (data available
upon request).
To test whether the synonymous cytosine798thymine
(Asp266Asp) substitution of rs7669 change the secondary
structure of mRNA we did an mfold analysis of MTIF3
mRNA. Our analysis indicates that rs7669 in exon 5 results
in an apparent change in the mRNA secondary structure
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Figure 1: Quantiﬁcation of MTIF3 mRNA levels. MTIF3 mRNA
levels in Epstein-Barr virus (EBV) transfected B-lymphocytes
from individuals carrying the three diﬀerent rs7669 genotypes,
normalized to the housekeeping genes beta-actin and cyclophilin.
mRNA levels were found to be signiﬁcantly lower in TT genotypes
compared to CC genotypes (P = .0163) using Student’s t-test.
and slightly higher energy for mRNA folding (dG) compared
with the dG of the wild-type mRNA folding (data available
upon request).
3.2. RNA Expression. To further investigate possible con-
sequences of the synonymous polymorphism rs7669 we
studied transcriptional activity of the MTIF3 gene by
measuring mRNA expression levels using qRT-PCR. We
found that MTIF3 mRNA levels were signiﬁcantly lower
(P = .0163) in cells from individuals carrying the TT
genotype compared to individuals with the CC genotype
(Figure 1). No signiﬁcant diﬀerence of MTIF3 mRNA levels
was found between cells from individuals carrying CT
and CC genotypes (P = .266). Testing both T-containing
genotypes together (TT/CT) versus CC, the MTIF3 mRNA
decrease was close to signiﬁcance (P = .0518). Similar
results were observed using the Mann-Whitney U test. Since
individuals were chosen based on their rs7669 genotype
without restriction to their neurological status, we also
compared expression data from patients versus controls,
which showed no signiﬁcant association (P = .0795).
4. Discussion
Our ﬁndings strengthen the hypothesis that the MTIF3
rs7669 variant may be involved in the etiology of sporadic
PD, because of the signiﬁcant association of the TT/CT
versus the CC genotype in a Swedish sample set. Abahuni
et al. (2007) have previously investigated the MTIF3 rs7669
polymorphism in a German case-control material consisting
of patients with positive familial history of PD as well as
sporadic cases [17]. The previous study found no signiﬁcant
association of the TT/CT genotypes with sporadic PD (P =
.0540), while results from our data set showed a signiﬁcant
association (P = .0473). Interestingly, Abahuni et al.
(2007) showed an association of increased CT genotypes and4 Parkinson’s Disease
Table 1: Association analysis of MTIF3 rs7669 genotype and allele frequencies in Parkinson’s disease (PD).
MTIF3 Familial PD (n=90) Sporadic PD (n=291) Combined samples (n=381) Controls (n=322)
Genotypes
CC (%) 59 (65.6) 168 (57.7) 227 (59.6) 211 (65.5)
CT (%) 28 (31.1) 108 (37.1) 136 (35.7) 96 (29.8)
TT (%) 3 (3.3) 15 (5.2) 18 (4.7) 15 (4.7)
χ2a P = .8513 P = .1335 P = .2439
Alleles
C (%) 146 (81.1) 444 (76.3) 590 (77.4) 518 (80.4)
T (%) 34 (18.9) 138 (23.7) 172 (22.6) 126 (19.6)
χ2b P = .8393 P = .0778 P = .1693
Odds ratio 1.045 (0.686–1.59) 0.783 (0.596–1.03) 0.834 (0.644–1.08)
Combined genotypes
CC/CT (%) 87 (96.7) 276 (94.8) 363 (95.3) 307 (95.3)
TT (%) 3 (3.3) 15 (5.2) 18 (4.7) 15 (4.7)
χ2b P = .5867 P = .7761 P = .9853
Odds ratio 1.42 (0.401–5.01) 0.899 (0.432–1.87) 0.985 (0.488–1.99)
TT/CT (%) 31 (34.4) 123 (42.3) 154 (40.4) 111 (34.5)
CC (%) 59 (65.6) 168 (57.7) 227 (59.6) 211 (65.5)
χ2b P = .9961 P = .0473 P = .1049
Odds ratio 0.999 (0.612–1.63) 1.39 (1.01–1.93) 1.29 (0.948–1.75)
aChi-square test (χ2) (2DF) for 2 ×3 contingency table,
bχ2 (1DF) for 2 ×2 contingency table.
decreased TT genotypes among sporadic cases (P = .0345)
and in combined samples (P = .0073) compared to controls.
The rs7669 variant might be in linkage disequilibrium
with some other real disease causing locus in MTIF3 or
in some other gene in its vicinity and this locus may
diﬀer between ethnical populations, although no other
known MTIF3 polymorphisms have been reported to be in
linkage disequilibrium with rs7669 on chr13: 26,907,780–
26,922,711.Theresultsfromthetwostudiesarecontraryand
could possibly be explained by that the two sample series
were collected from diﬀerent countries and there might be
as m a l le ﬀect of background population on the association,
although this is unlikely as both our study and the previous
one report similar allele frequencies that are in Hardy-
Weinburg equilibrium.
To date, the only two genetic studies on MTIF3 and PD
are Abahuni et al. (2007) and the present study. Our results
indicate that the TT/CT genotypes might be more common
among sporadic PD cases than controls, strengthening the
involvement of mitochondrial dysfunction in PD. We could
also show that the B-lymphocytes from individuals carrying
the TT genotype contain signiﬁcantly less MTIF3 mRNA
comparedtocellsfromindividualscarryingtheCCgenotype
(P = .0163). This suggests that the TT genotype aﬀects
MTIF3 mRNA levels although it cannot be fully excluded
that individuals with this genotype also carry additional
genetic variants aﬀecting the mRNA levels. By dividing the
samples into patients and controls without respect to their
genotype, we show that the decrease in expression of MTIF3
mRNA is not due too PD (P = .0795). Mechanisms by which
synonymous polymorphisms predispose to disease are not
wellunderstood,butseveralpossibilitieshavebeensuggested
including that they might aﬀect mRNA transcriptional
activity, mRNA stability, secondary mRNA structure, or at
the protein level, synthesis, folding, and thereby turnover or
function [25]. We performed a structure analysis in silico
to investigate if the synonymous polymorphism rs7669 in
MTIF3 could induce an alteration of the secondary mRNA
structure. Our ﬁndings indicate that rs7669 results in a
change the in mRNA secondary structure and that the
polymorphism has the potential to aﬀect folding and mRNA
stability. However, no strong conclusions can be drawn
from the artiﬁcial conditions used for modeling secondary
structures in silico.
5. Conclusion
In summary we show that a genetic variant of MTIF3
is associated with sporadic PD in Sweden, supporting
mitochondrial involvement in the disease. We have also
demonstrated that the TT genotype leads to a decreased
expression of MTIF3 mRNA. Further genetic studies are
needed in larger materials to conﬁrm these genetic ﬁndings.
Studies of the MTIF3 protein at the cellular level are
also needed to understand possible cellular sites at which
alterations of MTIF3 levels may aﬀect function.
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